Cellular and Humoral Immunity to SARS-CoV-2 Infection in Multiple Sclerosis Patients on Ocrelizumab and Other Disease-Modifying Therapies: A Multi-Ethnic Observational Study.

"Potential Conflicts of Interest I.K. served on the scientific advisory board for Biogen Idec, Genentech, Alexion, EMDSerono; received consulting fees from Roche; and received research support from Guthy‐Jackson Charitable Foundation, National Multiple Sclerosis Society, Biogen Idec, Serono, Genzyme, and Genentech/Roche; he receives royalties from Wolters Kluwer for “Top 100 Diagnosis in Neurology” (co‐written with Jose Biller). G.J.S. received honoraria from BMS, Eli Lilly and Genentech, and research support from BMS, Genentech, Lupus Research Alliance, NIH‐NIAMS, NIH‐NIAID, and NIH‐NILB. M.K. is on the scientific advisory board for NexImmune and Genentech and received research support from Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Genentech, the Mark Foundation, NIH‐NIGMS, and NIH‐NCI. C.R. and R.P. are employees and shareholders of F. Hoffmann‐La Roche. M.J.M. reported the following potential competing interests: laboratory research and shareholder of F. Hoffmann‐La Roche Ltd. clinical trials contracts for vaccines or MAB versus SARS‐CoV‐2 with Lilly, Pfizer, and Sanofi; personal fees for Scientific Advisory Board service from Merck, Meissa Vaccines, and Pfizer; contract funding from USG/HHS/BARDA for research specimen characterization and repository; research grant funding from USG/HHS/NIH for SARS‐CoV‐2 vaccine and MAB clinical trials. L.Z.R. served on the scientific advisory board for Biogen, Genentech, Celgene, and Novartis and received research support from Consortium of Multiple Sclerosis Centers; Biogen; and Genentech. M.C. is an employee and shareholder of Genentech, Inc. K.H. is a former employee of Genentech, Inc. J.P. is an employee of Genentech, Inc. and shareholder of F. Hoffmann‐La Roche. T.E.B., R.C., Z.R., K.P., S.E., Y.Y., and A.S. have nothing to disclose."

"This work was supported by an unrestricted investigator‐initiated grant from Genentech. Editorial assistance for the figures and tables, furnished by Sarah Nordquist, PhD, of Health Interactions, Inc, was provided by F. Hoffmann‐La Roche Ltd."